Overview

High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.
Phase:
Phase 3
Details
Lead Sponsor:
Hackensack Meridian Health
Hackensack University Medical Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Interferon-alpha
Interferons